As more treatments continue to enter the market for multiple myeloma (MM), the cost of associated treatments is expected to continue climbing, with the researchers of the study emphasizing the need for more effective and options to help mitigate costs.
A new French study is highlighting the high cost burden associated with multiple myeloma (MM), as well as variability in treatments used in later lines of therapy. The findings were published in The European Journal of Health Economics.
As more treatments continue to enter the market for MM, the cost of associated treatments is expected to continue climbing, with the researchers of the study emphasizing the need for more effective and options to help mitigate costs.
“Understanding patient [health care resource utilization] patterns, disease burden, and health-related expenditure is important when evaluating the potential value of new treatments and facilitates targeted improvements in MM management,” explained the researchers. “Analyses of health insurance databases can guide public health care decisions, monitor various types of medical expenditures, inform epidemiological studies, evaluate medical practices or health system experimentations, and can be used for international comparisons.”
The researchers included real-world data from 6400 patients diagnosed with MM between 2013 and 2018, finding an average annual cost of €58,300 (approximately $62,500). Notably, costs were highest in the first year after diagnosis, with a mean total annual cost per patient in the first exceeding €72,400 (approximately $77,600) and the monthly exceeding €7100 (approximately $7600).
The cost of treatment and hospitalizations contributed the most to costs, with an overall rate of 6.3 hospitalizations per patient per year. Nearly all (96.6%) patients underwent some type of hospitalization for any cause, and had at least 1 overnight hospital stay (93.1%). Notably, hospitalization accounted for a greater proportion (48.6%) of total costs in the first year after diagnosis than the average of the rest of the years of follow-up (38.1%).
With each line of therapy (LOT), the monthly costs associated with treatment increased. Monthly costs increased from €2447 (approximately $2600) during the first LOT to €7026 (approximately $7500) during fifth LOT and subsequently.
“Increase in hospitalisation costs associated with subsequent LOT was likely related to the increasing age and decreasing health of patients requiring ongoing treatment for MM,” described the researchers. “This is supported by a retrospective study of hospitalised French patients, which identified an association between age and duration of hospital stay. The cost of hospitalisations for an event of interest constituted a greater proportion of hospitalisation costs among patients at later LOT, indicating that declining patient condition conferred a greater burden to the health care system beyond the cost of drugs.”
Health care resource utilization was lower for patients who received stem cell transplantation, although their hospital stays were associated with higher costs, largely due to the more expensive procedure.
Nearly all (97.1%) patients received an identifiable treatment throughout the study period, with the most frequent regimens being those that included bortezomib. Bortezomib-based regimens accounted for 62.2% of the 8865 regimens, and 96.7% of patients received the combination as their first LOT. During second and third LOT, lenalidomide-based regimens were most common. By the fourth line of therapy and later, the researchers identified 37 different regimens.
Reference
Bessou A, Colin X, Nascimento J, et al. Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France usingthe Système National des Données de Santé (SNDS) database:a retrospective cohort study. Eur J Health Econ. Published online May 25, 2022. doi:10.1007/s10198-022-01463-9
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: HHS' Funding Flat; Mifepristone Safety; Insulin Shortage
March 25th 2024Flat funding for Health and Human Services (HHS) leaves critical health initiatives stagnant; Supreme Court weighs tightening regulations on abortion pill; manufacturing delay sparks access concerns for insulin medication.
Read More
Fracture Risk Lowest for Alendronate, Pamidronate Use During MM Treatment
March 21st 2024In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from facilitating jaw degradation and reducing vertebral fracture risk among patients being treated for multiple myeloma.
Read More
CMS is highly likely to negotiate the price of the obesity medication semaglutide in the coming years; many health care providers are trying to determine whether their cyberattack insurance will help cover their losses after the Change Healthcare hack; the US life expectancy increased for the first time in 2 years.
Read More